129 related articles for article (PubMed ID: 10698678)
1. Catabolites of cholesterol synthesis pathways and forskolin as activators of the farnesoid X-activated nuclear receptor.
Howard WR; Pospisil JA; Njolito E; Noonan DJ
Toxicol Appl Pharmacol; 2000 Mar; 163(2):195-202. PubMed ID: 10698678
[TBL] [Abstract][Full Text] [Related]
2. Regulation of ileal bile acid-binding protein expression in Caco-2 cells by ursodeoxycholic acid: role of the farnesoid X receptor.
Campana G; Pasini P; Roda A; Spampinato S
Biochem Pharmacol; 2005 Jun; 69(12):1755-63. PubMed ID: 15935148
[TBL] [Abstract][Full Text] [Related]
3. The nuclear receptor for bile acids, FXR, transactivates human organic solute transporter-alpha and -beta genes.
Landrier JF; Eloranta JJ; Vavricka SR; Kullak-Ublick GA
Am J Physiol Gastrointest Liver Physiol; 2006 Mar; 290(3):G476-85. PubMed ID: 16269519
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia downregulates farnesoid X receptor via a hypoxia-inducible factor-independent but p38 mitogen-activated protein kinase-dependent pathway.
Fujino T; Murakami K; Ozawa I; Minegishi Y; Kashimura R; Akita T; Saitou S; Atsumi T; Sato T; Ando K; Hara S; Kikugawa K; Hayakawa M
FEBS J; 2009 Mar; 276(5):1319-32. PubMed ID: 19187229
[TBL] [Abstract][Full Text] [Related]
5. 5Alpha-bile alcohols function as farnesoid X receptor antagonists.
Nishimaki-Mogami T; Kawahara Y; Tamehiro N; Yoshida T; Inoue K; Ohno Y; Nagao T; Une M
Biochem Biophys Res Commun; 2006 Jan; 339(1):386-91. PubMed ID: 16300737
[TBL] [Abstract][Full Text] [Related]
6. Role of bile acids and bile acid receptors in metabolic regulation.
Lefebvre P; Cariou B; Lien F; Kuipers F; Staels B
Physiol Rev; 2009 Jan; 89(1):147-91. PubMed ID: 19126757
[TBL] [Abstract][Full Text] [Related]
7. The farnesoid X receptor induces very low density lipoprotein receptor gene expression.
Sirvent A; Claudel T; Martin G; Brozek J; Kosykh V; Darteil R; Hum DW; Fruchart JC; Staels B
FEBS Lett; 2004 May; 566(1-3):173-7. PubMed ID: 15147890
[TBL] [Abstract][Full Text] [Related]
8. Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation.
Journe F; Laurent G; Chaboteaux C; Nonclercq D; Durbecq V; Larsimont D; Body JJ
Breast Cancer Res Treat; 2008 Jan; 107(1):49-61. PubMed ID: 17333335
[TBL] [Abstract][Full Text] [Related]
9. Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus.
Capello A; Moons LM; Van de Winkel A; Siersema PD; van Dekken H; Kuipers EJ; Kusters JG
Am J Gastroenterol; 2008 Jun; 103(6):1510-6. PubMed ID: 18510604
[TBL] [Abstract][Full Text] [Related]
10. FXR: a metabolic regulator and cell protector.
Wang YD; Chen WD; Moore DD; Huang W
Cell Res; 2008 Nov; 18(11):1087-95. PubMed ID: 18825165
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of ATP8B1 expression leads to specific downregulation of the bile acid sensor FXR in HepG2 cells: effect of the FXR agonist GW4064.
Martínez-Fernández P; Hierro L; Jara P; Alvarez L
Am J Physiol Gastrointest Liver Physiol; 2009 May; 296(5):G1119-29. PubMed ID: 19228886
[TBL] [Abstract][Full Text] [Related]
12. Discovery and optimization of non-steroidal FXR agonists from natural product-like libraries.
Nicolaou KC; Evans RM; Roecker AJ; Hughes R; Downes M; Pfefferkorn JA
Org Biomol Chem; 2003 Mar; 1(6):908-20. PubMed ID: 12929628
[TBL] [Abstract][Full Text] [Related]
13. FXR: a promising target for the metabolic syndrome?
Cariou B; Staels B
Trends Pharmacol Sci; 2007 May; 28(5):236-43. PubMed ID: 17412431
[TBL] [Abstract][Full Text] [Related]
14. VPAC1 expression is regulated by FXR agonists in the human gallbladder epithelium.
Chignard N; Mergey M; Barbu V; Finzi L; Tiret E; Paul A; Housset C
Hepatology; 2005 Sep; 42(3):549-57. PubMed ID: 16037943
[TBL] [Abstract][Full Text] [Related]
15. The farnesoid X receptor controls gene expression in a ligand- and promoter-selective fashion.
Lew JL; Zhao A; Yu J; Huang L; De Pedro N; Peláez F; Wright SD; Cui J
J Biol Chem; 2004 Mar; 279(10):8856-61. PubMed ID: 14684751
[TBL] [Abstract][Full Text] [Related]
16. The role of FXR in disorders of bile acid homeostasis.
Eloranta JJ; Kullak-Ublick GA
Physiology (Bethesda); 2008 Oct; 23():286-95. PubMed ID: 18927204
[TBL] [Abstract][Full Text] [Related]
17. Correlation of farnesoid X receptor coactivator recruitment and cholesterol 7alpha-hydroxylase gene repression by bile acids.
Bramlett KS; Yao S; Burris TP
Mol Genet Metab; 2000 Dec; 71(4):609-15. PubMed ID: 11136553
[TBL] [Abstract][Full Text] [Related]
18. Identification of farnesoid X receptor modulators by a fluorescence polarization-based interaction assay.
Han KC; Kim JH; Kim KH; Kim EE; Seo JH; Yang EG
Anal Biochem; 2010 Mar; 398(2):185-90. PubMed ID: 19913492
[TBL] [Abstract][Full Text] [Related]
19. The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases.
Niesor EJ; Flach J; Lopes-Antoni I; Perez A; Bentzen CL
Curr Pharm Des; 2001 Mar; 7(4):231-59. PubMed ID: 11254888
[TBL] [Abstract][Full Text] [Related]
20. Bile-acid-activated receptors: targeting TGR5 and farnesoid-X-receptor in lipid and glucose disorders.
Fiorucci S; Mencarelli A; Palladino G; Cipriani S
Trends Pharmacol Sci; 2009 Nov; 30(11):570-80. PubMed ID: 19758712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
